Smaller Biopharma M&A on Upswing, Deals Expected to Continue Through 2024

This was a short week due to the Memorial Day holiday. However, there were several small acquisitions announced by big players. Merck on Wednesday announced a $1.3 billion upfront payment, and $1.7 billion in potential milestones, to buy EyeBio and its first-in-class trispecific antibody Restoret, marking the company's return to the ophthalmology space after nearly a decade.